INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications

Show full item record

Bookmark or cite this item:

Files in this item

File Description Format
PDF 0217OSLIR_SHETH_proof_v2.pdf (398KB) (no description provided) PDF
Title: An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications
Author(s): Dunn, Evan N.; Hariprasad, Seenu M.; Sheth, Veeral S.
Subject(s): anti-VEGF vascular endothelial growth factor epidermal growth factor receptor
Abstract: The vitreoretinal community will remember 2016 as the year that unfavorable anti–platelet-derived growth factor (anti-PDGF) clinical trial results ended the development of Fovista (pegpleranib; Ophthotech, New York, NY) and Rinucumab (Regeneron, Tarrytown, NY). The failure of these trials reaffirmed how important the innovations made in 2006 with anti-vascular endothelial growth factor (anti-VEGF) were to our field and our patients. Evan N. Dunn, MD, and Veeral S. Sheth, MD, were tasked with analyzing and dissecting the anti-PDGF clinical trials — beginning with the basic science behind anti-PDGF. They will also review novel, multitarget approaches to our diseases, as well as unique routes of delivery such as topical and suprachoroidal administration. Reading this article leads one to appreciate how high the anti-VEGF class of molecules has set the bar for the treatment of vitreoretinal disease. Although recent clinical trial results have been a disappointment to our community (and our patients), we should be reassured by the fact that many development programs are strongly underway investigating novel approaches to treat back-of-the-eye disorders. Drs. Dunn and Sheth's insights will be highly valued by our community.
Issue Date: 2017-02
Publisher: Slack
Citation Info: Dunn E, Hariprasad S, Sheth V. An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. Ophthalmic Surg Lasers Imaging Retina. 2017; 48: 100-104. doi: 10.3928/23258160-20170130-02
Type: Article
Description: SLACK Incorporated’s journal copyright agreements enable authors funded by the National Institutes of Health (NIH) to deposit their accepted manuscripts to PubMed Central for posting 12 months following publication by SLACK Incorporated. The agreement also allows posting of accepted manuscripts on authors’ institutional repositories, with the exception of open access repositories, 12 months following publication by SLACK Incorporated. Authors should include a link to the final published article on the journal website. SLACK Incorporated will retain copyright for these articles, which prohibits republication elsewhere, and SLACK Incorporated will retain the right to charge a fee for the final published versions of these articles in whatever format they appear.
ISSN: 2325-8160
Sponsor: Dr. Dunn reports no relevant financial disclosures. Dr. Sheth has received personal fees from Alimera, Genentech, and Allergan outside the submitted work. Dr. Hariprasad is a consultant for Alcon, Allergan, Bayer, OD-OS, Clearside Biomedical, Ocular Therapeutix, Janssen, Leica, Spark, and Regeneron.
Date Available in INDIGO: 2018-02-15

This item appears in the following Collection(s)

Show full item record


Country Code Views
United States of America 59
China 15
Russian Federation 10
Ukraine 3
United Kingdom 2


My Account


Access Key